TITLE

Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents

AUTHOR(S)
Rockstroh, Juergen K.; Soriano, Vicente; Plonski, Frank; Bansal, Meena; Fätkenheuer, Gerd; Small, Catherine B.; Asmuth, David M.; Pialoux, Gilles; Mukwaya, Geoffrey; Jagannatha, Shyla; Heera, Jayvant; Pineda, Juan A.
PUB. DATE
April 2015
SOURCE
HIV Clinical Trials;04/01/2015, p72
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: One of the more clinically relevant co-morbidities in HIV-infected patients is the development of progressive liver disease due to hepatitis B virus (HBV) or hepatitis C virus (HCV). In addition, hepatotoxicity has been observed with prolonged use of antiretroviral agents. Objective: To evaluate the hepatic safety of maraviroc in combination with other antiretroviral agents in HIV-1-infected subjects co-infected with HCV and/or HBV. Methods: In this 148-week randomized, double-blind, placebo-controlled, multicentre study (NCT01327547), subjects received maraviroc twice daily (n = 70) or placebo (n = 67) in combination with other antiretroviral agents. Primary endpoint: the percentage at week 48 of subjects with Grade 3 and Grade 4 ALT abnormalities, defined as >5 × upper limit of normal (ULN) if baseline ALT ≤ ULN or >3.5 × baseline if baseline ALT>ULN in the maraviroc versus the placebo arm. Results: At week 48, one subject in each group had met the primary endpoint definition. No subjects met protocol-defined liver stopping criteria and there were no cases of Hy's law or treatment-related hepatobiliary serious adverse events. No significant difference in change from baseline in enhanced liver fibrosis or hepatic elastography was observed between groups. Treatment-related hepatobiliary adverse events were reported in one and two subjects receiving maraviroc and placebo, respectively; discontinuations due to treatment-related AEs occurred in four and two subjects receiving maraviroc and placebo, respectively; two deaths were reported in the placebo group. Conclusions: The use of maraviroc does not increase hepatotoxicity in HIV-1-infected subjects co-infected with HCV and/or HBV through 48 weeks of treatment.
ACCESSION #
102341195

 

Related Articles

  • Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. van Lelyveld, Steven F. L.; Drylewicz, Julia; Krikke, Maaike; Veel, Ellen M.; Otto, Sigrid A.; Richter, Clemens; Soetekouw, Robin; Prins, Jan M.; Brinkman, Kees; Mulder, Jan Willem; Kroon, Frank; Middel, Ananja; Symons, Jori; Wensing, Annemarie M. J.; Nijhuis, Monique; Borghans, José A. M.; Tesselaar, Kiki; Hoepelman, Andy I. M.; null, null // PLoS ONE;7/24/2015, Vol. 10 Issue 7, p1 

    Objective: The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week...

  • Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. Macías, J.; Viloria, M.; Rivero, A.; Santos, I.; Márquez, M.; Portilla, J.; Di Lello, F.; Camacho, A.; Sanz-Sanz, J.; Ojeda, G.; Mata, R.; Gómez-Mateos, J.; Pineda, J. // European Journal of Clinical Microbiology & Infectious Diseases;Aug2012, Vol. 31 Issue 8, p2083 

    The aim of this study was to analyze serum changes in mediators of fibrogenesis and in non-invasive markers of liver fibrosis among HIV/HCV-coinfected patients starting maraviroc (MVC)-based antiretroviral therapy. Patients included in this prospective pilot study met the following criteria: (1)...

  • Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era. Boyd, Mark A.; Hill, Andrew M. // PharmacoEconomics;2010 Supplement, Vol. 28, p17 

    Despite the success of combination antiretroviral therapy (ART) in improving clinical outcomes, treatment failure remains a significant challenge, particularly for highly treatment-experienced patients. This review evaluates current issues in the management of HIV-infected, treatment-experienced...

  • Does HCV make HIV infection worse? Mascolini, Mark // Research Initiative/Treatment Action!;Summer2014, Vol. 19 Issue 1, p20 

    The article discusses impact of hepatitis C virus (HCV) infection on HIV infection. Topics discussed include impact of HCV infection on mortality of HIV people, on response to combination antiretroviral therapy (cART), and on clinical outcomes and progression to AIDS. Two U.S. studies on HCV/HIV...

  • A Single-Blind randomized controlled trial to evaluate the effect of extended counseling on uptake of pre-antiretroviral care in Eastern Uganda.  // Trials;2011, Vol. 12 Issue 1, p184 

    The article reports on a Single-Blind randomized controlled trial that evaluates the effect providing post-test counseling on uptake of pre-antiretroviral (ARV) care for newly diagnosed people living with HIV (PLHIV) in Eastern Uganda. In this participants from three public recruitment centres...

  • A combination strategy for enhancing linkage to and retention in HIV care among adults newly diagnosed with HIV in Mozambique: study protocol for a site-randomized implementation science study. Elul, Batya; Lahuerta, Maria; Abacassamo, Fatima; Lamb, Matthew R.; Ahoua, Laurence; McNairy, Margaret L.; Tomo, Maria; Horowitz, Deborah; Sutton, Roberta; Mussa, Antonio; Gurr, Danielle; Jani, Ilesh // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background Despite the extraordinary scale up of HIV prevention, care and treatment services in sub- Saharan Africa (SSA) over the past decade, the overall effectiveness of HIV programs has been significantly hindered by high levels of attrition across the HIV care continuum. Data from...

  • Which do You Treat First -- HCV or HIV? Kemper, Carol A. // Infectious Disease Alert;Aug2008, Vol. 27 Issue 11, p131 

    The article discusses the results of a study which found that hepatotoxicity of antiretroviral drugs reduced after successful treatment of chronic hepatitis C in HIV-infected patients. It references a study by P. Labarga et al. published in the 2007 issue of the "Journal of Infectious Diseases."...

  • HIV-positive people with HCV have worse response to first antiretroviral combination.  // HIV Treatment ALERTS!;Mar2014, p36 

    The article presents a study on the impact of hepatitis C virus (HCV) in people with HIV infection. The researchers applied accepted statistical methods to identify how HCV impacted response to antiretrovirals examined by four results. The study reveals that people with HCV and HIV gained fewer...

  • Nevirapine hastens liver fibrosis in HIV/HCV coinfection.  // Reactions Weekly;6/26/2004, Issue 1007, p6 

    Discusses research being done on the association of nevirapine that contains highly active antiretroviral therapy regimens with liver fibrosis and fibrosis progression in HIV and hepatitis C virus patients. Reference to a study by J. Marcías et al., published in the March 26, 2004 issue of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics